Piramal Pharma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ajay G. Piramal, on behalf of the Promoter and Promoter Group of Piramal Pharma Limited, has filed a declaration under SEBI's Takeover Regulations confirming that no encumbrance (pledge, charge, or similar) has been created on any shares or securities of the company during the financial year 2024-2025. This is a routine annual compliance filing required from promoters. The declaration means the promoter group's shareholding remains unencumbered for the full fiscal year.
Neutral to mildly positive — it reassures shareholders that the promoter group did not pledge any of their holdings during the year, indicating no immediate liquidity stress from the promoter side.